Nasdaq

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
Nasdaq

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
ascopubs.org

A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung ...

Developing behavioral intervention to support molecular testing of patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...